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Metabolic syndrome is the cluster of diseases, which is manifested by 
central obesity, impaired glucose tolerance, lipodystrophy, and high blood 
pressure. These metabolic syndrome-related traits significantly increase the 
risk of type 2 diabetes, adverse cardiac events, stroke, and hepatic steatosis. 
In the past decade, several organizations have proposed different diagnostic 
criteria. The use of traditional Chinese medicine to treat metabolic syndrome 
has received increasing attention due to its wide availability. In this paper, 
we report a case of three patients with metabolic syndrome with improved 
administration of 7.5 g of Kangen-karyu extract per day for 6 months. We 
present and discuss evidence supporting the possibility of using Kangen-
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1. Introduction
Metabolic syndrome, a major public health problem 
worldwide today, is a cluster of clinical, metabolic, and 
biochemical abnormalities, such as central obesity, high 
blood pressure, impaired glucose tolerance, and dyslip-
idemia. These metabolic syndrome-related traits signifi-
cantly elevate the risk of type 2 diabetes mellitus, adverse 
cardiovascular events, stroke, and hepatic steatosis. The 
pathogenesis of metabolic syndrome is multifactorial, 
with the interplay of environmental, nutritional, and ge-
netic factors [1-3]. Thus, metabolic syndrome has become 
one of the major burdens of the health care system.
The concept of metabolic syndrome was first presented 
by Kylin in 1923, who described a syndrome involving 
hypertension, hyperglycemia, and gout [4]. However, this 
concept did not attract much attention until Dr. Reav-
en mentioned syndrome X, clustering of metabolic risk 
factors, in 1988, which is similar to metabolic syndrome 
[5]. The WHO (World Health Organization) and EGIR 
(European Group for the Study of Insulin Resistance) re-
leased their diagnostic criteria for metabolic syndrome [6,7]. 
The definition of metabolic syndrome in Japan, which is 
characterized by the accumulation of visceral fat with the 
co-occurrence of several risk factors, was established in 
2005 [8].
Epidemiological studies demonstrated that a condition 
clustering several risk factors like metabolic syndrome 
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will lead to a greater risk of cardiovascular diseases than 
a single risk factor [9-11]. The accumulation of visceral fat 
is essential for the diagnosis of metabolic syndrome and 
is considered to be located upstream of the cascade clus-
tering several risk factors and subsequent cardiovascular 
diseases. Therefore, the main purpose of the treatment of 
metabolic syndrome is the effective reduction of multiple 
risk factors and the following cardiovascular diseases 
through the reduction of visceral fat. In the treatment of 
metabolic syndrome, oriental medicine is an outstanding 
example of alternative and complementary medicine with 
a long history, a unique theoretical system, and a variety 
of herbal remedies. Many traditional Chinese medicine 
(TCM) has been tested for the treatment of metabolic 
syndrome. We have conducted pre-clinical animal experi-
ments to investigate the effectiveness of multi-target treat-
ment of TCM for various human diseases. In our previous 
studies, Kangen-karyu (a crude drug consisting of Salviae 
Miltiorrhizae Radix, Cnidii Rhizoma, Carthami Flos, Pae-
oniae Radix, Aucklandiae Radix, and Cyperi Rhizoma, 
as shown in Table 1; Guan-Yuan-Ke-Li in Chinese), a 
TCM modified from Kan-shin No. 2 (Guan-xin No. 2 in 
Chinese) [12], may play a protective role against metabolic 
syndrome [13-15]. Kangen-karyu has been used clinically as 
a treatment for cardiovascular disease, including angina 
pectoris and cerebrovascular diseases [16,17]. The results of 
our previous study provide important evidence that this 
prescription ameliorates metabolic syndrome.
Based on these results, Kangen-karyu was administered 
to three patients with metabolic syndrome, and report its 
therapeutic usefulness.
Table 1. Composition of Kangen-karyu.





Cnidii Rhizoma Cnidium officinale Makino Umbelliferae
Paeoniae Radix Paeonia lactiflora Pallas Paeoniaceae
Carthami Flos Carthamus tinctorius L. Compositae
Aucklandiae Radix Aucklandia lappa Dcne. Compositae
Cyperi Rhizoma Cyperus rotundus L. Cyperaceae
2. Case Presentation
2.1 Case 1
A 68-year-old male with hypertension, hypercholes-
terolemia, borderline diabetes, and obesity reports an 
improvement in metabolic syndrome when administered 
Kangen-karyu extract. This patient subsequently changed 
his lifestyle and continued to receive conventional treat-
ments: antihypertensive drugs (amlodin: 5 mg/day, azilva: 
20 mg/day) and an antilipidemic agent (lipitor: 5 mg/day). 
However, he came to our hospital, seeking to recover his 
functional level with medicine including herbal medicine. 
Kangen-karyu prescription (7.5 g/day) was administered 
three times a day. Before Kangen-karyu prescription 
administration, his initial anthropometric measurements 
included a BMI of 30.3 kg/m2: body weight 82.6 kg (182.1 
lb), height 165 cm (5.41 ft), and an abdominal circumfer-
ence of 105.8 cm (3.47 ft), which classified him as obese. 
In the blood pressure test, his systolic blood pressure 
(SBP)/diastolic blood pressure (DBP) was 133/85 mmHg. 
Serum hemoglobin A1c (HbA1c) or glycated hemoglobin 
was 7.3%, displaying poorly regulated blood glucose. 
Serum lipids levels were as follows: total cholesterol: 
230 mg/dL, low-density lipoprotein (LDL)-cholesterol: 
142 mg/dL, LDL-cholesterol/high-density lipoprotein 
(HDL)-cholesterol: 2.3, and triglycerides: 353 mg/dL, 
indicating dyslipidemia. When Kangen-karyu extract was 
administered for 6 months, BMI and abdominal circum-
ference were slightly reduced. The levels of triglycerides, 
total cholesterol, LDL-cholesterol, LDL-cholesterol/
HDL-cholesterol, and HbA1c were reduced. Meanwhile, 
other parameters such as liver and kidney function pa-
rameters [aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), urea nitrogen and creatinine (Cr)] 
were not affected by Kangen-karyu extract administration. 
However, physical and subjective symptoms such as 
headache, feeling of heaviness in the head, and mottled 
skin have improved. In addition, the tongue coating was 
slightly improved when Kangen-karyu was administered. 
Herein, we present evidence supporting the use of Kan-
gen-karyu prescription for metabolic syndrome.
2.2 Case 2
Kangen-karyu extract was effective for a 64-year-old 
woman with hypertension and hypercholesterolemia. This 
patient also changed her lifestyle and continues to receive 
existing treatments: antihypertensive drugs (amlodin: 5 
mg/day, micardis: 20 mg/day), but has not received hy-
polipidemia drugs. She presented to our hospital, seeking 
to recover her functional level with herbal medicine, and 
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was administered 7.5 g of Kangen-karyu extract per day. 
Before Kangen-karyu prescription administration, her 
initial anthropometric measurements included a BMI of 
25.2 kg/m2: body weight 58.0 kg (127.8 lb), height 152 
cm (4.99 ft), and an abdominal circumference of 90.5 
cm (2.97 ft), which classified her as obese. In the blood 
pressure test, her SBP/DBP was 133/88 mmHg. Serum 
HbA1c was 5.7%, displaying regulated blood glucose. 
Serum lipids levels were as follows: total cholesterol: 246 
mg/dL, LDL-cholesterol: 179 mg/dL, HDL-cholesterol: 
54 mg/dL: LDL-cholesterol/HDL-cholesterol: 3.3, and 
triglycerides: 183 mg/dL, indicating dyslipidemia. After 
6 months, administration of Kangen-karyu prescription 
showed a slight decrease in BMI and abdominal cir-
cumference. Her SBP/DBP was reduced from 133/80 to 
115/77 mmHg. The level of total cholesterol was reduced 
from 246 to 235 mg/dL. The elevated level of LDL-cho-
lesterol was slightly decreased, and HDL-cholesterol was 
slightly elevated on treatment with Kangen-karyu pre-
scription during the follow-up period. At that time, oral 
administration of Kangen-karyu prescription significantly 
decreased the elevated serum triglyceride level. Hepatic 
functional parameters (AST and ALT) also decreased at 
the 6-month follow-up. However, there was no change 
in HbA1c for Kangen-karyu treatment. Regarding the 
score using the questionnaire, it showed amelioration to 
75% of the level on non-administration. The physical and 
subjective symptoms involving headache, stiff shoulders, 
feeling heavy in the head, and mottled skin had improved. 
According to the tongue diagnosis, there was a notable 
improvement in vessels below the tongue following the 
treatment of Kangen-karyu prescription for 6 months, 
although the tongue color, fur color, and thickness amelio-
rated only slightly. The results reported herein identified 
the therapeutic usefulness of Kangen-karyu to treat blood 
stasis.
2.3 Case 3
A 65-year-old man with high blood pressure, dys-
lipidemia, type 2 diabetes, chronic kidney disease, and 
hyperuricemia was previously diagnosed with metabolic 
syndrome. Subsequently, the patient continued to receive 
existing treatments: an antilipidemic agent (livaro: 1 
mg/day) and antihypertensive agent (micardis: 20 mg/
day). In addition, Kangen-karyu prescription (7.5 g/
day) was treated three times a day for 6 months. Before 
Kangen-karyu prescription administration, his initial an-
thropometric measurements included a BMI of 27.4 kg/
m2: body weight 81.6 kg (179.7 lb), height 173 cm (5.68 
ft), and an abdominal circumference of 98.4 cm (3.23 ft), 
which classified him as obese. His SBP/DBP was 130/86 
mmHg. Serum HbA1c was 6.1%, displaying poorly con-
trolled blood glucose. Serum lipids levels were as follows: 
total cholesterol: 216 mg/dL, LDL-cholesterol: 118 mg/
dL, HDL-cholesterol: 46 mg/dL, and triglycerides: 306 
mg/dL, indicating hyperlipidemia. In addition, his serum 
Cr level of 1.69 mg/dL had moderately impaired renal 
function (eGFR 33.0 ml/min/1.73 m2) according to the 
Modification of Diet in Renal Disease equation [18]. The 
level of serum uric acid was 8.6 mg/dL, representing hy-
peruricemia derived from kidney disease. This patient was 
also an alcoholic, and alcohol consumption was assessed 
by questioning. He was categorized as a heavy consumer 
( ≧ 30 g alcohol/day) according to the average daily al-
cohol consumption proposed by Agarwal [19]. Therefore, 
enzymes related to the hepatobiliary system and myocar-
dial infarction were determined to assess their effects on 
the relationship between metabolic syndrome and alco-
hol consumption. ALT, gamma-glutamyl transpeptidase 
(γ-GTP), and creatine phosphokinase (CPK) were found to 
be poorly controlled. There were no significant changes in 
the activities of AST, alkaline phosphatase, or lactate de-
hydrogenase. During the administration of Kangen-karyu 
extract, BMI and the abdominal circumference showed 
no changes, but the systolic/diastolic blood pressure de-
creased from 130/86 to 126/70 mmHg. The level of total 
cholesterol had reduced from 216 to 197 mg/dL at the 
6-month follow-up. The increased levels of LDL-choles-
terol and LDL-cholesterol/HDL-cholesterol were slightly 
reduced on treatment with Kangen-karyu prescription. 
Oral treatment of Kangen-karyu prescription significantly 
decreased the elevated triglyceride level. Other parameters 
such as eGFR, Cr, uric acid, AST, ALT, γ-GTP, and CPK 
were improved by the Kangen-karyu treatment. At that 
time, the physical and subjective symptoms such as cold 
limbs, fatigue, and insomnia had partially disappeared. 
There was a slight improvement in the tongue coating. 
Kangen-karyu extract exhibits good efficacy in the admin-
istration of lifestyle-induced metabolic syndrome.
3. Discussion
Therapy for metabolic syndrome is multifaceted, as is 
the syndrome itself. Effective preventive approaches in-
clude lifestyle modification, mainly weight loss, exercise 
and diet, and the treatment comprises the appropriate use 
of pharmacological drugs to decrease the particular risk 
factors [20]. TCM has received much attention as potential 
sources of novel therapeutic drugs due to their multiple 
beneficial effects and absence of side effects toxic and/
or toxicity [21]. Up to now, many TCM have been test-
ed for the treatment of metabolic syndrome. We chose 
Kangen-karyu, TCM modified from herbal formular 
DOI: https://doi.org/10.30564/jim.v10i1.3230
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of Kan-shin No. 2 [12]. It has been clinically used as an 
administration for cardiovascular disorders, involving 
cerebrovascular disorder and angina pectoris [16,17]. Kan-
gen-karyu is being proposed as a new therapeutic material 
based on preclinical studies related to various human 
diseases [13,14,22-27]. To add to these findings, we reported 
evidence supporting its preventive and/or therapeutic 
potential against metabolic syndrome in a rat model 
[14]. Treatment of Kangen-karyu significantly improved 
high-fructose-induced metabolic syndrome such as hyper-
tension, hyperlipidemia, and hyperglycemia, through the 
reductions of triglyceride and cholesterol contents with the 
modulation of sterol regulatory element-binding protein-1 
(SREBP-1) and the nuclear factor-kappa B signaling 
pathway in the liver. We also reported the lipid-regulatory 
activity of Kangen-karyu on type 2 diabetes-induced dys-
lipidemia [15]. The results of our pre-clinical experiment 
provide scientific evidence that the use of this prescription 
for the treatment of metabolic syndrome is becoming 
increasingly popular due to its wide availability. We ad-
ministered Kangen-karyu extract to metabolic syndrome 
patients, and evaluated its treatment-based usefulness.
In the present cases, there was an improvement in met-
abolic syndrome following the treatment of Kangen-karyu 
prescription for 6 months. Most notably, the levels of se-
rum triglycerides, total cholesterol, and LDL-cholesterol 
decreased following the administration of Kangen-karyu 
prescription. The body weight, BMI, abdominal circum-
ference, and blood pressure reduced compared with before 
treatment, as shown in Figure 1. At that time, the somatic 
and subjective symptoms had partially improved. Here, 
we present a therapeutic effect of Kangen-karyu based on 
metabolic parameters.
In TCM, tongue diagnosis plays an important role in 
the organ’s meridians and conditions. The characteristic of 
the tongue reflects the condition of organ and imbalance 
of Qi and blood. TCM practitioners observe the tongue 
appearance such as the body color and coating of tongue 
to determine the pathogenic factors. The color of tongue 
reflects the state of the Yin organs, blood, and nutritive Qi. 
Coating of tongue is observed from the tip to root and re-
flects the hot or cold aspects of the body [28,29]. The tongue 
provides a geographic map of organ systems; characteris-
tics of the tongue in each of these areas provide informa-
tion critical to the TCM diagnosis [28]. Therefore, tongue 
diagnosis was evaluated by TCM doctors who collected 
Figure 1. Clinical effects of Kangen-karyu.
DOI: https://doi.org/10.30564/jim.v10i1.3230
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the information with a digital camera. The researchers 
checked tongue characteristics, such as the coat color, coat 
weight, coat surface, tongue action, and vessels below 
the tongue. In case 2, there was a notable improvement in 
vessels below the tongue following the treatment of Kan-
gen-karyu extract for 6 months, although the tongue color, 
fur color, and thickness ameliorated only slightly. Most 
notably, vessels below the tongue were recovered by Kan-
gen-karyu administration to near-normal levels. These in 
cases 1 and 3 revealed a slight improvement in the tongue 
coating of the treatment group.
It has been proposed that metabolic syndrome develops 
as a result of the reciprocal action of several environmen-
tal factors. In particular, alcohol consumption is one of the 
most prevalent habits in the general population [30]. The 
harmful effects of heavy alcohol consumption are due to 
an increase in plasma triacylglycerol and increased blood 
pressure [31,32]. Each of these factors is a component of 
metabolic syndrome. In case 3, interesting findings were 
obtained with regard to enzymes related to the hepato-
biliary system and myocardial infarction: the levels of 
AST, ALT, γ-GTP, and CPK decreased compared with 
non-administration. Although the association of metabolic 
syndrome with alcohol consumption is complex and con-
troversial, as both protective and detrimental effects have 
been reported [30,33], we report evidence to support the use 
of Kangen-karyu as an adjunctive therapy for patients 
with lifestyle-induced metabolic syndrome. The admin-
istration for metabolic syndrome involves the manage-
ment of a cluster of chronic diseases such as high blood 
pressure, dyslipidemia, diabetes mellitus, and obesity. 
However, TCM has received much attention as a source of 
multi-target strategies due to its multiple beneficial effects 
and absence of toxic and/or side effects. The present cases 
provide strong evidence to support the administration of 
Kangen-karyu extract as a therapeutic agent to prevent the 
progression of metabolic syndrome.
The definition of metabolic syndrome in Japan, which 
is characterized by the accumulation of visceral fat, ac-
companied by the concurrence of multiple risk factors, 
was established in 2005 [8]. The accumulation of visceral 
fat is essential for the diagnosis of metabolic syndrome 
and is considered to be located upstream of the cascade 
clustering multiple risk factors and subsequent cardiovas-
cular diseases. Therefore, the primary aim of treatment for 
metabolic syndrome is the effective reduction of multiple 
risk factors and subsequent cardiovascular diseases by 
lower visceral fat. TCM is an excellent system in com-
plementary and alternative medicine. It shows marked 
and unique potential in the management of metabolic 
syndrome. Its potential in the treatment of metabolic syn-
drome has not been reviewed, but is promising regarding 
the development of new, effective therapies. Therapy with 
Kangen-karyu is aimed to correct maladjustments and re-
store the self-regulatory ability of the body to ameliorate 
metabolic syndrome. The present study provides import-
ant evidence that the use of Kangen-karyu may become a 
new therapeutic strategy against metabolic syndrome.
4. Conclusions
We report scientific evidence supporting the use of 
Kangen-karyu as an adjunctive therapy for patients with 
metabolic syndrome. Kangen-karyu shows good efficacy 
in the treatment of patients with metabolic syndrome.
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